Jean‐Gabriel Fuzibet

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 905 citations · Full text

Medicine, Genetics, Hematology +15

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Jean‐Luc Harousseau, Michel Attal, Xavier Leleu et al. · PubMed · 2006 · 335 citations

Medicine, Pharmacology, Pharmacotherapy +15

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Philippe Moreau, Hervé Avet‐Loiseau, Thierry Façon et al. · Blood · 2011 · 302 citations

Medicine, Hematology, Oncology +17

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Hervé Avet‐Loiseau, Florent Malard, L. Campion et al. · Blood · 2010 · 127 citations · Full text

Medicine, Hematology, Oncology +14

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

Philippe Moreau, Michel Attal, Brigitte Pegourié et al. · Blood · 2010 · 124 citations

Medicine, Oncology, Immunotherapy +4